Tirzepatide vs Semaglutide: The Research Comparison
Tirzepatide vs semaglutide is the most consequential comparison in this compound class, because the two are separated by one additional receptor and a substantial difference in reported outcomes. This page sets out what actually distinguishes them, what the head to head trial found, how the schedules and costs compare, and where the newer triple agonist retatrutide sits alongside both. Everything discussed here is supplied for laboratory research use only.
Research pens and kits in stock
Retatrutide
Retatrutide
Weight Loss
Weight Loss
Recovery
Recovery
Cosmetic
Table of Contents
Tirzepatide vs Semaglutide at a Glance
| Semaglutide | Tirzepatide | |
|---|---|---|
| Receptors | GLP-1 only | GLP-1 and GIP |
| Generation | First | Second |
| Licensed UK brands | Wegovy, Ozempic | Mounjaro |
| Weekly amounts studied | 0.25 to 2.4mg | 2.5 to 15mg |
| Our research format | 8mg kit, £160 | 40mg kit, £180 |
The Receptor Difference That Drives Everything
The tirzepatide vs semaglutide question comes down to one receptor. Semaglutide acts at GLP-1 alone, while tirzepatide acts at GLP-1 and additionally at GIP, the other major incretin receptor. That single addition is the entire pharmacological difference between them, and it is the reason the second generation displaced the first as the reference compound in this class.
GIP activity appears to complement GLP-1 activity rather than duplicate it, which is why the combination produced more than an incremental change. Understanding this progression matters because it also explains what retatrutide adds on top, covered in our reta peptide guide.
What the Head to Head Trial Showed
Unusually for this field, tirzepatide vs semaglutide was tested directly rather than only across separate trials. The SURPASS-2 study randomised participants with type 2 diabetes to tirzepatide at 5mg, 10mg or 15mg weekly against semaglutide at 1mg weekly, which is the comparison most often quoted.
Tirzepatide produced greater reductions in both HbA1c and body weight across all three of its amounts. That is a genuine head to head result and it is the strongest single piece of evidence in this comparison. The important caveat is that semaglutide was tested at 1mg weekly rather than at the 2.4mg amount later used in obesity trials, so the comparison is not against semaglutide at its highest studied amount.
Anyone quoting this trial without that caveat is overstating it. Registered trial records and published results are indexed on PubMed.
Amounts and Schedules Compared
| Stage | Semaglutide weekly | Tirzepatide weekly |
|---|---|---|
| Starting amount | 0.25mg | 2.5mg |
| Intermediate | 0.5mg then 1mg | 5mg then 10mg |
| Highest studied | 2.4mg | 15mg |
| Escalation | Stepped over months | Stepped over months |
In tirzepatide vs semaglutide terms the amounts are not comparable as numbers, which is the most common misreading of this table. Tirzepatide is used at roughly six times the milligram figure of semaglutide, so a milligram of one is not equivalent to a milligram of the other. Both escalate in steps, and in both cases the reported tolerability belongs to the stepped schedule rather than to the endpoint amount.
Tolerability Compared
On tirzepatide vs semaglutide tolerability, the adverse event profile is broadly similar in character, which is expected given the shared GLP-1 mechanism. Gastrointestinal events dominate in both: nausea, vomiting, diarrhoea and constipation, predominantly mild to moderate, clustered around escalation steps rather than running at a constant rate.
Neither compound is free of that burden and neither is dramatically worse in kind. The same pattern recurs with retatrutide, and the fuller discussion including trial exclusion criteria is in our side effects guide.
Cost Compared, Properly
Comparing tirzepatide vs semaglutide on cost per milligram is misleading and worth explaining rather than simply doing. Our semaglutide kit is £160 for 8mg, which is £20.00 per milligram. Our tirzepatide kit is £180 for 40mg, which is £4.50 per milligram. On those figures semaglutide looks four times more expensive, and that impression is false.
| Semaglutide 8mg kit | Tirzepatide 40mg kit | |
|---|---|---|
| Price | £160 | £180 |
| Cost per mg | £20.00 | £4.50 |
| Weeks at the lowest studied amount | 32 at 0.25mg | 16 at 2.5mg |
| Weeks at the highest studied amount | 3.3 at 2.4mg | 2.7 at 15mg |
Read the bottom two rows instead. Measured in weeks of a published schedule rather than in milligrams, the two kits are far closer than the per milligram figures suggest, and semaglutide covers longer at the low end. Cost per milligram is a valid comparison within one compound and an invalid one across compounds used at different scales. Our price index applies it the correct way.
Compare the full range
Retatrutide
Retatrutide
Weight Loss
Weight Loss
Recovery
Recovery
Cosmetic
Where Retatrutide Fits as the Third Generation
Retatrutide adds a third receptor, glucagon, on top of the GLP-1 and GIP activity tirzepatide already has. Where the incretin receptors reduce energy intake, glucagon receptor activity raises energy expenditure, so the third generation addresses both sides of the equation rather than one.
The critical difference is evidence maturity rather than mechanism. Semaglutide and tirzepatide have both completed regulatory review and are licensed in the UK, with post marketing surveillance behind them. Retatrutide has completed Phase 2, published in the New England Journal of Medicine, and remains in Phase 3 with no licence anywhere in the world. Newer does not mean better established, and for comparative research that distinction usually matters more than the extra receptor. Our retatrutide versus Mounjaro guide takes that comparison further.
Choosing Between Them for Research
On tirzepatide vs semaglutide for comparative work, the honest answer is usually both, because a result for one generation is only interpretable against a characterised baseline. Semaglutide is the deepest evidenced compound in the class and tirzepatide is the current reference standard, so a programme holding only the newer compound has no baseline to measure against.
If only one is possible, choose by the question. Work anchored to the largest published literature points to semaglutide. Work anchored to current clinical practice points to tirzepatide. Work exploring the frontier points to retatrutide, with the evidence caveat understood. Supplier checks for any of them are in our buyer guide, and the full catalogue is on the research peptides UK page.
What Neither Compound Has Established
Both sides of the tirzepatide vs semaglutide comparison share the same gap, and it is rarely mentioned in summaries of either. Neither has published substantial data on what happens after discontinuation over the long term. The trials measured effect during treatment, and the follow up needed to characterise what follows is thin for both.
That matters for interpreting any comparison between them. A difference measured at forty or seventy two weeks tells you which produced more change while being administered. It does not tell you which produced more durable change, because that question has largely not been asked. Treating a during treatment difference as a permanent one is an inference the data does not support for either compound.
Designing a Comparison That Produces an Answer
If you are running work that turns on tirzepatide vs semaglutide, a few design points determine whether the result means anything.
- Match on schedule stage rather than on milligrams, since the compounds operate at different scales and equal masses are not equivalent.
- Escalate both according to their own published schedules, because compressing either produces an unstudied protocol rather than a faster one.
- Source both as research grade from the same supply route, so batch handling is a constant rather than a hidden variable.
- Record delivered amounts rather than dialled amounts for both, since priming error otherwise enters one arm more than the other.
- Hold cold chain identical across arms, because differential degradation would masquerade as a difference in effect.
That last point is the one most often missed. If one compound sat warm in transit and the other did not, any difference observed belongs to the courier rather than to the pharmacology.
Legal Position in the United Kingdom
The research materials we supply are not licensed medicines. Although semaglutide and tirzepatide both have licensed counterparts prescribed in the UK, research grade material has not been dispensed through a regulated pharmacy chain, holds no authorisation from the MHRA, cannot lawfully be supplied for human use, and cannot be advertised with therapeutic claims under Advertising Standards Authority rules. Retatrutide has no licensed counterpart at all.
Anyone seeking treatment should speak to a registered UK prescriber about the licensed options, which exist and are appropriate for that purpose. Nothing on this page is medical advice.
Tirzepatide vs Semaglutide FAQ
What is the difference between tirzepatide and semaglutide?
Semaglutide acts at the GLP-1 receptor alone. Tirzepatide acts at GLP-1 and additionally at GIP. That single extra receptor is the entire pharmacological difference and the reason tirzepatide became the reference compound.
Which performed better in a head to head trial?
Tirzepatide produced greater reductions in HbA1c and body weight in SURPASS-2, at 5mg, 10mg and 15mg weekly. The caveat is that semaglutide was tested at 1mg weekly, not at the 2.4mg amount used in later obesity trials.
Why are the milligram amounts so different?
The compounds work at different scales. Semaglutide is used from 0.25mg to 2.4mg weekly and tirzepatide from 2.5mg to 15mg, so a milligram of one is not equivalent to a milligram of the other.
Is tirzepatide cheaper than semaglutide?
Per milligram yes, at £4.50 against £20.00, but that comparison is invalid across compounds used at different scales. Measured in weeks of a published schedule the two kits are far closer.
How does retatrutide compare with both?
It adds a third receptor, glucagon, which raises energy expenditure rather than only reducing intake. It is also the least established of the three, having completed Phase 2 with no licence anywhere.
Are these licensed in the UK?
The pharmaceutical products are, as Wegovy, Ozempic and Mounjaro, on prescription. The research materials we supply are not licensed medicines and are for laboratory use only.
